304 related articles for article (PubMed ID: 15308348)
1. Long-term protection against SHIV89.6P replication in HIV-1 Tat vaccinated cynomolgus monkeys.
Maggiorella MT; Baroncelli S; Michelini Z; Fanales-Belasio E; Moretti S; Sernicola L; Cara A; Negri DR; Buttò S; Fiorelli V; Tripiciano A; Scoglio A; Caputo A; Borsetti A; Ridolfi B; Bona R; ten Haaft P; Macchia I; Leone P; Pavone-Cossut MR; Nappi F; Ciccozzi M; Heeney J; Titti F; Cafaro A; Ensoli B
Vaccine; 2004 Sep; 22(25-26):3258-69. PubMed ID: 15308348
[TBL] [Abstract][Full Text] [Related]
2. Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine.
Cafaro A; Caputo A; Fracasso C; Maggiorella MT; Goletti D; Baroncelli S; Pace M; Sernicola L; Koanga-Mogtomo ML; Betti M; Borsetti A; Belli R; Akerblom L; Corrias F; Buttò S; Heeney J; Verani P; Titti F; Ensoli B
Nat Med; 1999 Jun; 5(6):643-50. PubMed ID: 10371502
[TBL] [Abstract][Full Text] [Related]
3. Vectored Gag and Env but not Tat show efficacy against simian-human immunodeficiency virus 89.6P challenge in Mamu-A*01-negative rhesus monkeys.
Liang X; Casimiro DR; Schleif WA; Wang F; Davies ME; Zhang ZQ; Fu TM; Finnefrock AC; Handt L; Citron MP; Heidecker G; Tang A; Chen M; Wilson KA; Gabryelski L; McElhaugh M; Carella A; Moyer C; Huang L; Vitelli S; Patel D; Lin J; Emini EA; Shiver JW
J Virol; 2005 Oct; 79(19):12321-31. PubMed ID: 16160159
[TBL] [Abstract][Full Text] [Related]
4. Control of viral replication and disease onset in cynomolgus monkeys by HIV-1 TAT vaccine.
Ensoli B; Cafaro A
J Biol Regul Homeost Agents; 2000; 14(1):22-6. PubMed ID: 10763887
[TBL] [Abstract][Full Text] [Related]
5. Innate anti-viral immunity is associated with the protection elicited by the simian immunodeficiency virus (SIV) live attenuated virus vaccine in cynomolgus monkeys.
Goletti D; Macchia I; Leone P; Pace M; Sernicola L; Pavone-Cossut MR; Maggiorella MT; Cafaro A; Ensoli B; Titti F
Med Sci Monit; 2006 Oct; 12(10):BR330-40. PubMed ID: 17006396
[TBL] [Abstract][Full Text] [Related]
6. SHIV89.6P pathogenicity in cynomolgus monkeys and control of viral replication and disease onset by human immunodeficiency virus type 1 Tat vaccine.
Cafaro A; Caputo A; Maggiorella MT; Baroncelli S; Fracasso C; Pace M; Borsetti A; Sernicola L; Negri DR; Ten Haaft P; Betti M; Michelini Z; Macchia I; Fanales-Belasio E; Belli R; Corrias F; Buttò S; Verani P; Titti F; Ensoli B
J Med Primatol; 2000 Aug; 29(3-4):193-208. PubMed ID: 11085582
[TBL] [Abstract][Full Text] [Related]
7. The impact of early immune destruction on the kinetics of postacute viral replication in rhesus monkey infected with the simian-human immunodeficiency virus 89.6P.
Zhang ZQ; Schleif WA; Casimiro DR; Handt L; Chen M; Davies ME; Liang X; Fu TM; Tang A; Wilson KA; McElhaugh M; Carella A; Tan C; Connolly B; Hill S; Klein H; Emini EA; Shiver JW
Virology; 2004 Mar; 320(1):75-84. PubMed ID: 15003864
[TBL] [Abstract][Full Text] [Related]
8. Vaccine-induced, simian immunodeficiency virus-specific CD8+ T cells reduce virus replication but do not protect from simian immunodeficiency virus disease progression.
Engram JC; Dunham RM; Makedonas G; Vanderford TH; Sumpter B; Klatt NR; Ratcliffe SJ; Garg S; Paiardini M; McQuoid M; Altman JD; Staprans SI; Betts MR; Garber DA; Feinberg MB; Silvestri G
J Immunol; 2009 Jul; 183(1):706-17. PubMed ID: 19542473
[TBL] [Abstract][Full Text] [Related]
9. T-cell-mediated protective efficacy of a systemic vaccine approach in cynomolgus monkeys after SIV mucosal challenge.
Michelini Z; Negri DR; Baroncelli S; Catone S; Comini A; Maggiorella MT; Sernicola L; Crostarosa F; Belli R; Mancini MG; Farcomeni S; Fagrouch Z; Ciccozzi M; Rovetto C; Liljestrom P; Norley S; Heeney J; Titti F
J Med Primatol; 2004 Oct; 33(5-6):251-61. PubMed ID: 15525326
[TBL] [Abstract][Full Text] [Related]
10. Induction of neutralizing antibodies and Th1-polarized and CD4-independent CD8+ T-cell responses following delivery of human immunodeficiency virus type 1 Tat protein by recombinant adenylate cyclase of Bordetella pertussis.
Mascarell L; Fayolle C; Bauche C; Ladant D; Leclerc C
J Virol; 2005 Aug; 79(15):9872-84. PubMed ID: 16014948
[TBL] [Abstract][Full Text] [Related]
11. Multi-envelope HIV-1 vaccine devoid of SIV components controls disease in macaques challenged with heterologous pathogenic SHIV.
Zhan X; Martin LN; Slobod KS; Coleclough C; Lockey TD; Brown SA; Stambas J; Bonsignori M; Sealy RE; Blanchard JL; Hurwitz JL
Vaccine; 2005 Nov; 23(46-47):5306-20. PubMed ID: 16095768
[TBL] [Abstract][Full Text] [Related]
12. Immunization with HIV-1 SF162-derived Envelope gp140 proteins does not protect macaques from heterologous simian-human immunodeficiency virus SHIV89.6P infection.
Xu R; Srivastava IK; Kuller L; Zarkikh I; Kraft Z; Fagrouch Z; Letvin NL; Heeney JL; Barnett SW; Stamatatos L
Virology; 2006 Jun; 349(2):276-89. PubMed ID: 16527321
[TBL] [Abstract][Full Text] [Related]
13. Containment of infection in tat vaccinated monkeys after rechallenge with a higher dose of SHIV89.6P(cy243).
Borsetti A; Baroncelli S; Maggiorella MT; Moretti S; Fanales-Belasio E; Sernicola L; Tripiciano A; Macchia I; Michelini Z; Belli R; Farcomeni S; Pavone-Cossut MR; Negri D; Caputo A; Bellino S; Butto S; Titti F; Cafaro A; Ensoli B
Viral Immunol; 2009 Apr; 22(2):117-24. PubMed ID: 19326998
[TBL] [Abstract][Full Text] [Related]
14. Studies using a viral challenge and CD8 T cell depletions on the roles of cellular and humoral immunity in the control of an SHIV-89.6P challenge in DNA/MVA-vaccinated macaques.
Amara RR; Ibegbu C; Villinger F; Montefiori DC; Sharma S; Nigam P; Xu Y; McClure HM; Robinson HL
Virology; 2005 Dec; 343(2):246-55. PubMed ID: 16185742
[TBL] [Abstract][Full Text] [Related]
15. Heterologous envelope immunogens contribute to AIDS vaccine protection in rhesus monkeys.
Letvin NL; Huang Y; Chakrabarti BK; Xu L; Seaman MS; Beaudry K; Korioth-Schmitz B; Yu F; Rohne D; Martin KL; Miura A; Kong WP; Yang ZY; Gelman RS; Golubeva OG; Montefiori DC; Mascola JR; Nabel GJ
J Virol; 2004 Jul; 78(14):7490-7. PubMed ID: 15220422
[TBL] [Abstract][Full Text] [Related]
16. A molecular clone of simian-human immunodeficiency virus (DeltavpuSHIV(KU-1bMC33)) with a truncated, non-membrane-bound vpu results in rapid CD4(+) T cell loss and neuro-AIDS in pig-tailed macaques.
McCormick-Davis C; Dalton SB; Hout DR; Singh DK; Berman NE; Yong C; Pinson DM; Foresman L; Stephens EB
Virology; 2000 Jun; 272(1):112-26. PubMed ID: 10873754
[TBL] [Abstract][Full Text] [Related]
17. Rapid appearance of secondary immune responses and protection from acute CD4 depletion after a highly pathogenic immunodeficiency virus challenge in macaques vaccinated with a DNA prime/Sendai virus vector boost regimen.
Matano T; Kano M; Nakamura H; Takeda A; Nagai Y
J Virol; 2001 Dec; 75(23):11891-6. PubMed ID: 11689672
[TBL] [Abstract][Full Text] [Related]
18. No difference in Gag and Env immune-response profiles between vaccinated and non-vaccinated rhesus macaques that control immunodeficiency virus replication.
Nieuwenhuis I; Beenhakker N; Bogers WM; Otting N; Bontrop RE; Dubois P; Mooij P; Heeney JL; Koopman G
J Gen Virol; 2010 Dec; 91(Pt 12):2974-84. PubMed ID: 20826621
[TBL] [Abstract][Full Text] [Related]
19. Prolonged survival of vaccinated macaques after oral SIVmac239 challenge regardless of viremia control in the chronic phase.
Suh YS; Park KS; Sauermann U; Kim KS; Ahn SS; Franz M; Schulte R; Wilfingseder D; Stoiber H; Uberla K; Hunsmann G; Stahl-Hennig C; Sung YC
Vaccine; 2008 Dec; 26(51):6690-8. PubMed ID: 18694796
[TBL] [Abstract][Full Text] [Related]
20. DNA vaccination of macaques by a full genome HIV-1 plasmid which produces noninfectious virus particles.
Akahata W; Ido E; Shimada T; Katsuyama K; Yamamoto H; Uesaka H; Ui M; Kuwata T; Takahashi H; Hayami M
Virology; 2000 Sep; 275(1):116-24. PubMed ID: 11017793
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
